Yes. The procedure with prior notification (PPN) can be applied to new authorisation applications and indication extensions for medicinal products with orphan drug status. The additional fee for fast-track processing will always be applied. However, the flat-rate fee for new authorisation applications will be waived in view of the product’s orphan drug status.
No. If orphan drug status derives from Swiss prevalence data, there is no obligation to actively notify Swissmedic of changes in status abroad.
Applications for a temporary authorisation procedure are charged separately on the basis of the work involved.
Medicinal products with orphan drug or MUMS status are only exempt from the fee charged for new authorisation applications. All other applications (i.e. including applications for the procedure itself) are subject to the fees set out in the Fees Ordinance.
Whether or not the new Fees Ordinance is applied is determined by the date on which the application for a variation is received and not by when orphan drug or MUMS status was awarded, or by when the medicinal product in question was authorised. That means that applications for variations to medicinal products with orphan drug or MUMS status received on or after 1 January 2019 are subject to a fee.
“Significant benefit” still plays no role in assessing eligibility for and awarding ODS in Switzerland. The criteria set out in Art. 4 para. 1 let. adecies TPA are authoritative.
As long as the Swiss prevalence criteria set out in Art. 4 para. 1 let. adecies (1) TPA continue to be fulfilled, ODS will not be withdrawn in Switzerland.
The reporting obligation set out in Art. 5 para. 2 TPLO applies to the applicant/marketing authorisation holder in question.
No, Swissmedic issues ODS on the basis of statuses in countries with comparable medicinal product control and without reference to prevalence in Switzerland. Swiss prevalence data only become relevant if the status in other countries changes in any way (see Art. 6 TPLO).
Last modification 28.01.2020